Literature DB >> 34376805

Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.

Iman Abou Dalle1, Ali Bazarbachi2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34376805     DOI: 10.1038/s41409-021-01434-3

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.

Authors:  Christoph Schmid; Myriam Labopin; Arnon Nagler; Dietger Niederwieser; Luca Castagna; Reza Tabrizi; Michael Stadler; Jürgen Kuball; Jan Cornelissen; Jiri Vorlicek; Gerard Socié; Michele Falda; Lars Vindeløv; Per Ljungman; Graham Jackson; Nicolaus Kröger; Andreas Rank; Emmanuelle Polge; Vanderson Rocha; Mohamad Mohty
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Matthew Mei; Amandeep Salhotra; Samer Khaled; Ryotaro Nakamura; David Snyder; Margaret O'Donnell; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

3.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Authors:  Haley E Ramsey; Melissa A Fischer; Taekyu Lee; Agnieszka E Gorska; Maria Pia Arrate; Londa Fuller; Kelli L Boyd; Stephen A Strickland; John Sensintaffar; Leah J Hogdal; Gregory D Ayers; Edward T Olejniczak; Stephen W Fesik; Michael R Savona
Journal:  Cancer Discov       Date:  2018-09-05       Impact factor: 39.397

4.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Brian A Jonas; Vinod Pullarkat; Michael J Thirman; Jacqueline S Garcia; Andrew H Wei; Marina Konopleva; Hartmut Döhner; Anthony Letai; Pierre Fenaux; Elizabeth Koller; Violaine Havelange; Brian Leber; Jordi Esteve; Jianxiang Wang; Vlatko Pejsa; Roman Hájek; Kimmo Porkka; Árpád Illés; David Lavie; Roberto M Lemoli; Kazuhito Yamamoto; Sung-Soo Yoon; Jun-Ho Jang; Su-Peng Yeh; Mehmet Turgut; Wan-Jen Hong; Ying Zhou; Jalaja Potluri; Keith W Pratz
Journal:  N Engl J Med       Date:  2020-08-13       Impact factor: 91.245

5.  Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.

Authors:  Andrew H Wei; Pau Montesinos; Vladimir Ivanov; Courtney D DiNardo; Jan Novak; Kamel Laribi; Inho Kim; Don A Stevens; Walter Fiedler; Maria Pagoni; Olga Samoilova; Yu Hu; Achilles Anagnostopoulos; Julie Bergeron; Jing-Zhou Hou; Vidhya Murthy; Takahiro Yamauchi; Andrew McDonald; Brenda Chyla; Sathej Gopalakrishnan; Qi Jiang; Wellington Mendes; John Hayslip; Panayiotis Panayiotidis
Journal:  Blood       Date:  2020-06-11       Impact factor: 22.113

6.  Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.

Authors:  Maansi Joshi; Joselle Cook; Kristen McCullough; Ahmad Nanaa; Naseema Gangat; James M Foran; Hemant S Murthy; Mohamed A Kharfan-Dabaja; Lisa Sproat; Jeanne Palmer; Animesh Pardanani; Ayalew Tefferi; Kebede Begna; Michelle Elliot; Aref Al-Kali; Mrinal Patnaik; Mithun V Shah; William J Hogan; Mark R Litzow; Hassan B Alkhateeb
Journal:  Blood Cancer J       Date:  2021-03-04       Impact factor: 11.037

7.  Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.

Authors:  Ali Bazarbachi; Christoph Schmid; Myriam Labopin; Dietrich Beelen; Igor Wolfgang Blau; Victoria Potter; Riitta Niittyvuopio; Gerard Socié; Didier Blaise; Jaime Sanz; Fabio Ciceri; Iman Abou Dalle; Alexandros Spyridonidis; Gesine Bug; Jordi Esteve; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

8.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265

  8 in total
  1 in total

Review 1.  The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.

Authors:  Iman Abou Dalle; Ali Atoui; Ali Bazarbachi
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.